Cargando…

Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer

A 56-year old woman with BRCA-associated breast cancer and recurrent ovarian cancer was treated with a poly (ADP-ribose) polymerase enzyme (PARP) inhibitor, rucaparib, in the setting of dialysis-dependence which required dose modification. Rucaparib trough levels were obtained before and after dialy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harold, Justin A., Free, Stephanie C., Bradley, William H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223187/ https://www.ncbi.nlm.nih.gov/pubmed/30426062 http://dx.doi.org/10.1016/j.gore.2018.10.011

Ejemplares similares

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status
por: Saravi, Sayeh, et al.
Publicado: (2021)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
por: Kondrashova, Olga, et al.
Publicado: (2018)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
por: Yubero, Alfonso, et al.
Publicado: (2022)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

Emerging treatment options for ovarian cancer: focus on rucaparib
por: Mariappan, Lavanya, et al.
Publicado: (2017)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Cisplatin +/− rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer
por: Kalra, Maitri, et al.
Publicado: (2021)

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
por: Roy, Somnath, et al.
Publicado: (2022)

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile
por: Lorusso, Domenica, et al.
Publicado: (2020)

Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment
por: Grechko, Nikolay, et al.
Publicado: (2021)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
por: Abida, Wassim, et al.
Publicado: (2020)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
por: Swisher, Elizabeth M., et al.
Publicado: (2021)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
por: Dockery, LE, et al.
Publicado: (2017)

Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells
por: Cho, Hye-yon, et al.
Publicado: (2021)

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
por: Drew, Yvette, et al.
Publicado: (2016)

Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
por: Drew, Yvette, et al.
Publicado: (2016)

Evaluation of phototoxicity induced by the anticancer drug rucaparib
por: Mateos-Pujante, Alejandro, et al.
Publicado: (2022)

Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer
por: Monk, Bradley J, et al.
Publicado: (2021)

Correction: Rucaparib as a Salvage Treatment in Platinum-Sensitive Relapsed Ovarian Carcinoma: A Case Report
por: Biswas, Ghanashyam
Publicado: (2022)

Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
por: Lee, Chee Khoon, et al.
Publicado: (2019)

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
por: Oza, Amit M., et al.
Publicado: (2020)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models
por: Chan, Chung Ying, et al.
Publicado: (2022)

Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations
por: Wu, Maximillian S, et al.
Publicado: (2022)

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
por: Simmons, Andrew D., et al.
Publicado: (2020)

Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States
por: Guy, Holly, et al.
Publicado: (2018)

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
por: Lorusso, Domenica, et al.
Publicado: (2020)

The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity
por: Curtin, Nicola J
Publicado: (2020)

Recurrent mutations of BRCA1, BRCA2 and PALB2 in the population of breast and ovarian cancer patients in Southern Poland
por: Wojcik, P., et al.
Publicado: (2016)

Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity
por: Wang, Xian, et al.
Publicado: (2018)

Real‐World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10
por: Drew, Yvette, et al.
Publicado: (2019)

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”
por: Wallace, Katrine, et al.
Publicado: (2019)

Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10
por: Colomban, Olivier, et al.
Publicado: (2023)

Patterns of recurrence and metastasis in BRCA1/BRCA2‐associated breast cancers
por: Song, Yun, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_spbcm4tq1l993a74u4v59kgc06